US2013089498A1PendingUtilityA1

Compositions and methods related to profiling a plurality of cells based on peptide binding

Assignee: UNIV TEXASPriority: Mar 9, 2006Filed: Sep 27, 2012Published: Apr 11, 2013

Est. expiryMar 9, 2026(expired)· nominal 20-yr term from priority

Inventors:Renata Pasqualini Wadih Arap Mikhail G. Kolonin

C07K 7/06C07K 7/64C12N 15/1037A61P 35/00G01N 33/5759

PatentIndex Score

Cited by

References

Claims

Abstract

Methods and compositions are described for classifying cells and/or peptides that associate or bind with a particular characteristic pattern to a plurality of cells or cell lines. Aspects of the invention also include the use of peptide(s) having an appropriate binding characteristic to deliver a drug to a cell or cell population.

Claims

exact text as granted — not AI-modified

1 .- 31 . (canceled) 
     
     
         32 . A method of targeting a therapeutic agent or an imaging agent to an EphA5 receptor positive cancer cell in a subject, the method comprising administering to the subject a pharmaceutical composition comprising:
 a) the EphA5 cell targeting moiety; and   b) the therapeutic agent or the imaging agent.   
     
     
         33 . The method of  claim 32 , wherein an EphA5 receptor is on a surface of the cancer cell. 
     
     
         34 . The method of  claim 32 , wherein the subject is a human. 
     
     
         35 . The method of  claim 32 , wherein the EphA5 cell targeting moiety comprises a peptide. 
     
     
         36 . The method of  claim 35 , wherein the peptide is covalently modified. 
     
     
         37 . The method of  claim 35 , wherein the peptide is cyclic. 
     
     
         38 . The method of  claim 32 , wherein the EphA5 cell targeting moiety comprises an antibody. 
     
     
         39 . The method of  claim 38 , wherein the antibody is specific for EphA5 receptor only when upregulated on a surface of the cancer cell. 
     
     
         40 . The method of  claim 32 , wherein the therapeutic agent or the imaging agent comprises a radioisotope. 
     
     
         41 . The method of  claim 40 ,wherein the radioisotope is  213 Bi,  103 Pd,  133 Xe,  131 I,  68 Ge,  57 Co,  65 Zn,  85 Sr,  32 P,  35 S,  90 Y,  153 Sm,  153 Gd,  169 Yb,  51 Cr,  54 Mn,  75 Se,  113 Sn,  117 Sn,  186 Re,  166 Ho or  188 Re. 
     
     
         42 . The method of  claim 32 , wherein the therapeutic agent is a polypeptide capable of inducing cell death in the cell. 
     
     
         43 . The method of  claim 32 , wherein the therapeutic agent is an immunotherapeutic agent. 
     
     
         44 . The method of  claim 32 , Wherein the therapeutic agent is a chemotherapeutic agent. 
     
     
         45 . The method of  claim 32 , wherein the EphA5 cell targeting moiety is directly coupled to the therapeutic agent or the imaging agent. 
     
     
         46 . A method of treating an EphA5 receptor positive cancer cell in a subject, the method comprising administering a pharmaceutical composition comprising:
 a) an EphA5 cell targeting moiety; and   b) a therapeutic agent or an imaging agent,   
       to the subject. 
     
     
         47 . The method of  claim 46 , wherein an EphA5 receptor is on a surface of the cancer cell. 
     
     
         48 . The method of  claim 46 , wherein the subject is a human. 
     
     
         49 . The method of  claim 46 , wherein the EphA5 cell targeting moiety comprises a peptide. 
     
     
         50 . The method of  claim 49 , wherein the peptide is covalently modified. 
     
     
         51 . The method of  claim 50 , wherein the peptide is cyclic. 
     
     
         52 . The method of  claim 46 , wherein the EphA5 cell targeting moiety comprises an antibody. 
     
     
         53 . The method of  claim 52 , wherein the antibody is specific for an EphA5 receptor only when upregulated on a surface of the cancer cell. 
     
     
         54 . The method of  claim 46 , wherein the therapeutic agent or imaging agent comprises a radioisotope. 
     
     
         55 . The method of  claim 54 ,wherein the radioisotope is  213 Bi,  103 Pd,  133 Xe,  131 I,  68 Ge,  57 Co,  65 Zn,  85 Sr,  32 P,  35 S,  90 Y,  153 Sm,  153 Gd,  169 Yb,  51 Cr,  54 Mn,  75 Se,  113 Sn,  117 Sn,  186 Re,  166 Ho or  188 Re. 
     
     
         56 . The method of  claim 46 , wherein the therapeutic agent is a polypeptide capable of inducing cell death in the cell. 
     
     
         57 . The method of  claim 46 , wherein the therapeutic agent is an immunotherapeutic agent. 
     
     
         58 . The method of  claim 46 , wherein the therapeutic agent is a chemotherapeutic agent. 
     
     
         59 . The method of  claim 46 , wherein the EphA5 cell targeting moiety is directly coupled to the therapeutic agent or the imaging agent.

Join the waitlist — get patent alerts

Track US2013089498A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.